KR101760468B1 - New Sialic Acid Derivatives of Epothilone A and Method for Producing the Same - Google Patents

New Sialic Acid Derivatives of Epothilone A and Method for Producing the Same Download PDF

Info

Publication number
KR101760468B1
KR101760468B1 KR1020150187287A KR20150187287A KR101760468B1 KR 101760468 B1 KR101760468 B1 KR 101760468B1 KR 1020150187287 A KR1020150187287 A KR 1020150187287A KR 20150187287 A KR20150187287 A KR 20150187287A KR 101760468 B1 KR101760468 B1 KR 101760468B1
Authority
KR
South Korea
Prior art keywords
epothilone
epoa
sialic acid
derivative
galactose
Prior art date
Application number
KR1020150187287A
Other languages
Korean (ko)
Other versions
KR20170077422A (en
Inventor
송재경
파라줄리 프라카스
프라사드 판데이 라메스
이주호
김대희
우진석
Original Assignee
선문대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 선문대학교 산학협력단 filed Critical 선문대학교 산학협력단
Priority to KR1020150187287A priority Critical patent/KR101760468B1/en
Publication of KR20170077422A publication Critical patent/KR20170077422A/en
Application granted granted Critical
Publication of KR101760468B1 publication Critical patent/KR101760468B1/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)
    • C12Y204/01022—Lactose synthase (2.4.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99004—Beta-galactoside alpha-2,3-sialyltransferase (2.4.99.4)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a sialic acid derivative of epothilone A represented by the general formula (1) or (2), more specifically, to a sialic acid derivative represented by the following formula (1): (a) a β- (Epothilone A 6-O-β-D-glucoside, EpoA-Glc) and UDP-D-galactose were reacted with EpoA galactose derivative Galactosyl epothilone A, lac-epoA); And (b) the above-mentioned EpoA galactose derivative is reacted with?-2,3 sialyltransferase,? 2,3-SiaT or? -2,6-sialyltransferase (? -2,6 Sialyltransferase, α2,6-SiaT) with cytidine 5'-monophosphospho-N-acetyl neuraminic acid (CMP-NeuAc) to obtain a sialyl acid derivative of the formula (1'-sialyllactosyl epothilone Epothilone A (3'-SL-epoA) or a sialic acid derivative (6'-sialyllactosyl epothilone A, 6'-SL-epoA) And a process for producing the same.

Description

TECHNICAL FIELD The present invention relates to a novel epothilone A sialic acid derivative and a method for producing the same,

The present invention relates to a sialic acid derivative of epothilone A and a process for producing the same.

Microtubules are unique cytoskeletal structures composed of αβ-tubulin subunits and play an important role in numerous cellular processes, including dynamic function and / or cell structure maintenance and intracellular mass transfer for total cell tissue (. Akbari, V. et al, Avicenna J. Med biotechnol, 3: 167-75, 2011; La Ferla, B. et al, Nat Prod Rep, 28:...... 630-48, 2011).

The microtubule skeleton is an effective and proven target for chemotherapeutic agents for cancer, such as taxol, epothilones, discodermolide, and eleutherobin, which are already in clinical development stages (He , L. et al, Drug Discov Today , 6:.. 1153-64, 2001), the therapeutic agents are effective in treating various forms of cancer, such as lung cancer, breast cancer, uterine cancer, melanoma, and brain cancer as microtubule stabilizing material .

Among the above therapeutic agents, epothilones are a class of antibiotics discovered in the early 1990's when theoretically proved cytotoxicity and clinically promoted as anticancer agents (Rogalske, A. et al ., Toxicol . In Vitro , 28: 239-49, 2013; Shi , G. et al, J. Biomol Sstruct Dyn 30:.... 559-73, 2012), study of treating an epothilone to the human uterine cancer cell epothilone a mitosis It reveals that the failure and represents a mainly affect the unusual stability of the fine dynamic sogan polymerisation organ transport and cells induce cell functions such as signal transduction (Rogalske, A. et al, Toxicol in Vitro, 28:.. 239 -49, 2013; Altmann, KH et al ., ChemMed Chem , 4: 396-423, 2007). In addition, epothilone has the ability to drive the GTP-independent tubulin polymerization of cancer cells to maintain microtubule stabilization and stabilized microtubules at low drug concentrations in cells expressing P-glycoprotein (MRD-releasing protein) .

Many anticancer agents are inhibiting their pharmacological efficacy due to the reduction of intracellular drug accumulation or increase of drug release, the inactivation of drugs due to organic compounds including intracellular SH groups, or the solubility of anticancer drugs (Brabec, V. and Kasparkova , V., Drug Resist. Updat ., 8: 131-46, 2005; Tanaka, M. et al ., Anticancer Res., 31: 763-9, 2011; Xie, SK et al ., Chemotherapy , 55: 433 -40, 2009). Thus, many researchers have focused on carbohydrate moieties and sugar appendages, including therapeutic agents with low toxicity, improved solubility, and excellent cell recognition capabilities, bearing in mind that cancer cells consume a large amount of glucose compared to normal cells Tanaka, M. et al ., BMC Cancer, 13: 237, 2013; Tiwari, VK et al ., Mini Rev. Med . Chem. , 14: 1497-519, 2012).

Geldanamycin (GA), which was the most potent anticancer antibiotic candidate but was not used for severe toxicity, increased the therapeutic effect and solubility by using a carbohydrate analogue. Zelda, which did not exhibit anticancer activity due to inadequate internalization of cancer cells The sugar-binding analogs of naminucin are applied to antibody-directed enzyme prodrug therapy (ADEPT), which is a method of delivering modified analogues or inactive drugs along with enzymes such as β-glucosidase or galactosidase, . Glucose-GA, galactose-GA, and lactose-GA of the C17 position-modified geldanamycin were 3 to 40 times more potent than aglycon (Cheng, H. et al ., J. Med. Chem. 48: 645-52, 2005).

Glycosyltransferase plays an important role in the biosynthesis of oligosaccharides in the carbohydrates of antibiotics and is a major family of sugar neuraminic acid, sialic acid, which has a very diverse chemical structure at the terminal position of the oligosaccharide chain. (Traving, C. and Schauer, R., Cell Mol . Life Sci ., 54: 1330-49, 1998), which are present on the surface of cells and molecules and possess a variety of biological functions in cell recognition. Because these sugar molecules have a negative charge due to the amine group at position 5 and the carboxyl group at position 1, they can bind with positively charged molecules such as Ca 2 + and recognize specific antigens. Therefore, (Traving, C. and Schauer, R., Cell Mol . Life Sci ., 54: 1330-49, 1998; Yu, H. et al ., Nat . Protoc ., 1 : 2485-92, 2006). The recognition of host specific antigens by oligosaccharides and sialic acid derivatives of anticancer drugs has a great influence on the reduction of cancer formation and cancer treatment.

Accordingly, the present inventors have made intensive efforts to develop a sialic acid derivative of epothilone A, and as a result, found that epothilone A 6-O-β (4-galactosyltransferase, (Epothilone A 6-O-β-D-glucoside, EpoA-Glc) and UDP-D-galactose were reacted to prepare EpoA galactosyl derivative (Galactosyl epothilone A, lac-epoA) The resulting EpoA galactose derivative was reacted with α-2,3 sialyltransferase, α2,3-SiaT or α-2,6 sialyltransferase -acetyl neuraminic acid (CMP-NeuAc) in the presence of a cytotoxic agent such as 3'-sialyllactosyl epothilone A (1, 2, 6-SiaT) , 3'-SL-epoA) or a sialic acid derivative (6'-sialyllactosyl epothilone A, 6'-SL-epoA) of formula (2).

It is an object of the present invention to provide a novel sialic acid derivative of epothilone A represented by Chemical Formula (1) or Chemical Formula (2) which is a potential anti-cancer therapeutic agent which is specific to cancer cells and has reduced cytotoxicity and improved solubility.

Another object of the present invention is to provide a process for preparing a sialic acid derivative of epothilone A represented by the general formula (1) or (2) through enzymatic synthesis.

In order to achieve the above object, the present invention provides a sialic acid derivative of epothilone A represented by the general formula (1) or (2).

[Chemical Formula 1]

Figure 112015127422312-pat00001

(2)

Figure 112015127422312-pat00002

The present invention also provides a pharmaceutical composition comprising (a) Epothilone A 6-O-β-D-glucoside in the presence of a β-1,4-galactosyltransferase, preparing epoA galactosyl derivatives (Galactosyl epothilone A, lac-epoA) by reacting UDP-D-galactose with UDP-D-glucoside and EpoA-Glc; And (b) the above-mentioned EpoA galactose derivative is reacted with?-2,3 sialyltransferase,? 2,3-SiaT or? -2,6-sialyltransferase (? -2,6 Sialyltransferase, α2,6-SiaT) with cytidine 5'-monophosphospho-N-acetyl neuraminic acid (CMP-NeuAc) to obtain a sialyl acid derivative of the formula (1'-sialyllactosyl epothilone Epothilone A represented by formula (1) or (2), which comprises the step of preparing a sialic acid derivative (6'-sialyllactosyl epothilone A, 6'-SL-epoA) A method for producing a sialic acid derivative is provided.

According to the present invention, a method for producing a sialic acid derivative of epothilone A is a method for producing a sialic acid derivative (3'-sialyllactosyl epothilone A, 3 ') which is a potential anti-cancer therapeutic agent having specific cytotoxicity and improved solubility, -SL-epoA) or a sialic acid derivative of formula (2) (6'-sialyllactosyl epothilone A, 6'-SL-epoA).

Brief Description of the Drawings Fig. 1 is a schematic representation of an epothilone A (SEQ ID NO: 1) catalyzed by glycosyltransferases (YjiC), galactosyltransferases (ss1,4-GalT) and sialic acid transferases (a2,3- SiaT or a2,6- Is a schematic diagram showing the enzymatic synthesis process of the derivatives.
Fig. 2 shows the results of HPLC analysis and HR-LC-MS mass spectrometry of epothilone A 6-O- beta -D glucose synthesized from epothilone A.
FIG. 3 is a graph showing the effect of the epothilone A galactose derivative (lac-epoA) and epothilone A sialic acid derivatives (3'-SL-epoA and 6'-SL -epoA). < / RTI >
Figure 4 shows the HR-LC-ESI / MS mass spectrometry results of the synthesized epothilone A galactose derivative (lac-epoA) and epothilone A sialic acid derivatives (3'-SL-epoA and 6'-SL-epoA) .
Figures 5a, 5b and 5c show the synthesis of the synthesized epothilone A galactose derivative (lac-epoA) (a) and epothilone A sialic acid derivatives (3'-SL-epoA and 6'- ≪ 1 > H NMR spectra.
Figure 6 shows the results of physiological activity of human tumor cell lines HUVEC and HCT116 of epothilone A and synthesized epothilone A derivatives.

In the present invention, galactose or sialic acid is added to Epothilone A 6-O-? -D-glucoside (EpoA-Glc) synthesized from epothilone A, To prepare an epothilone A derivative represented by the formula (1) or (2).

Specifically, (a) Epothilone A 6-O-β-D-glucoside is produced in the presence of β-1,4-galactosyltransferase, β1,4- D-glucoside, EpoA-Glc) with UDP-D-galactose to prepare an EpoA galactosyl derivative (Galactosyl epothilone A, lac-epoA), and (b) reacting the EpoA galactose derivative In the presence of α-2,3 sialyltransferase, α2,3-SiaT or α-2,6 sialyltransferase, α2,6-SiaT, CMP (3'-sialyllactosyl epothilone A, 3'-SL-epoA) of the formula (1) or a compound of the formula (1) by reacting with a cytidine 5'-monophosphospho-N-acetyl neuraminic acid 2 (6'-sialyllactosyl epothilone A, 6'-SL-epoA).

Accordingly, in one aspect, the present invention relates to a sialic acid derivative of epothilone A represented by the following general formula (1) or (2).

[Chemical Formula 1]

Figure 112015127422312-pat00003

(2)

Figure 112015127422312-pat00004

In another aspect, the present invention relates to a method for producing the above-mentioned epothilone A sialic acid derivative represented by the above general formula (1) or (2).

Specifically,

(a) Epothilone A 6-O-β-D-glucoside (SEQ ID NO: 1) in the presence of β-1,4- , EpoA-Glc) with UDP-D-galactose to prepare an EpoA galactosyl derivative (Galactosyl epothilone A, lac-epoA); And

(b) The above-mentioned EpoA galactose derivative is reacted with an α-2,3 sialyltransferase, α2,3-SiaT or α-2,6 sialyltransferase -acetyl neuraminic acid (CMP-NeuAc) in the presence of a cytotoxic agent such as 3'-sialyllactosyl epothilone A (1, 2, 6-SiaT) , 3'-SL-epoA) or a sialic acid derivative (6'-sialyllactosyl epothilone A, 6'-SL-epoA) of formula (2).

The epothilone A 6-O-? -D-glucoside (EpoA-Glc) used in the step (a) is a glycoprotein derived from Bacillus licheniformis- derived glycoprotein YjiC (Uridine diphosphate glucosyltransferase ) And UDP-D-glucose. However, it is not particularly limited to these, and they may be obtained from natural sources or artificially synthesized and used.

The β-1,4-galactosyltransferase (β1,4-GalT) used in the step (a) is derived from Helicobacter pylori ATCC 43504, and the galactose is transferred from UDP-D-galactose to the receptor do.

The α-2,3 sialyltransferase (α2,3-SiaT) used in step (b) is derived from Pasteurella multocida (ATCC 15742), and the α-2,6 sialyltransferase α-2,6 sialyltransferase, α2,6-SiaT) was detected in Photobacterium damselae , Each transferring N-acetylneuraminic acid from the CMP-N-acetylneuraminic acid to the receptor per substance.

As the glycosyltransferase, commercially available ones, those derived from nature, and those produced by genetic recombination can be used, and they can be appropriately selected depending on the type of the monosaccharide to be transferred. In Example 1 of the present invention, a galactosyltransferase carries out a glycosyltransfer reaction to bind galactose. Further, a sialic acid transfer reaction is performed by a sialyltransferase to bind sialic acid to the galactose.

Epothilone binds to a protein called tubulin and blocks the formation of a microtubule, a key structure in cell division. By stopping the division of rapidly dividing cells such as cancer cells, .

In the present invention, sialic acid is acetylneuraminic acid, present on the surface of cells and molecules, and possesses various biological functions in cell recognition. Specifically, since the amine group at position 5 and the carboxyl group at position 1 have a negative charge, they can bind positively charged molecules such as Ca 2+ and can recognize specific antigens. Therefore, (Traving, C. and Schauer, R., Cell Mol. Life Sci., 54: 1130-49, 1998; Yu, H. et al ., N. Protoc., 1 : 2485-92, 2006).

The epothilone A derivative to which the monosaccharide or amino sugar of the present invention is bonded refers to an epothilone A analogue having a glycan chain. More specifically, it is characterized by a structure in which D-glucose is bound to the 6th O of epothilone A (EpoA 6-O-? -D-glucoside) and a monosaccharide is bonded to the D-glucose 4 position can do.

The monosaccharide can be represented by the general formula of Cn (H 2 O) n. The monosaccharide can be divided into three types of carbon tetra (tris), pentose (pentose) and hexose (hexose) depending on the number of carbon atoms. When the carbonyl group is an aldehyde group, it is called aldose, and when it is a ketone group, it is called ketoose. It can be obtained by extracting from natural products, or by hydrolyzing oligosaccharides, polysaccharides and the like, or chemically synthesized.

In addition, the monosaccharide has an asymmetric carbon atom, and since it has many stereoisomers, it has optical activity and is divided into two groups of D and L. The most simple aldose, glycerin aldehyde, is D-type, the sugar-derived sugar is D-type, and the symmetric form is L-type. A preferred monosaccharide in the present invention is the D series of hexose (hexose).

Specific examples include glucose, fructose, mannose, galactose, ribose and the like, most preferably galactose. Therefore, representative examples of monosaccharide-linked epothilone A derivatives of the present invention include " EpoA galactose derivatives ".

The derivatives of the present invention can be produced by reacting epothilone A derivatives obtained by further linking another monosaccharide to a monosaccharide-linked derivative in which a monosaccharide is transferred to D-glucose at the terminal EpoA 6 -O-? -D- glucoside as described above .

The monosaccharide which can be further transferred is the same as the monosaccharide described above. Preferably, an amino sugar is exemplified. The amino sugar is a sugar in which the hydroxyl group of the sugar is substituted with an amino group (-NH 2). The most widely available sugar in the natural world is glucosamine (2-amino-2-deoxy D-glucose) and galactosamine Dioxygalactose). Amino sugars are generally acetyl derivatives in which the amino group is substituted with an acetyl group.

An example of the preferred amino sugar in the present invention is sialic acid. Sialic acid is a generic term of several derivatives of neuraminic acid, which is an amino group containing 9 carbon atoms, and is a kind of monosaccharide having a complex structure having a carboxyl group, a ketone group and an acetamide group in one molecule.

A representative example of sialic acid is acetylneuraminic acid, which is an aldol condensate of pyruvic acid and acetylmannosamine. Of particular importance in the properties of the sialic acids is the presence of carboxy groups. Sialic acid is widely distributed at the non-reducing end of the glycoprotein / ganglioside, giving them acidic properties. Sialic acid is also responsible for a considerable portion of negatively charged cells. The sialic acid structure is basically observed as glycoproteins and glycolipids on N-linked and O-linked cell surface of cancer cells, and is directly related to cancer invasion and metastasis.

As described above, the present invention relates to a process for the production of epothilone A derivative, which is a process for producing an epothilone A derivative by first transferring monosaccharides such as secondary, tertiary and the like to primary monosaccharides, And an epothilone A derivative having a glycan chain bonded thereto.

Sialic acid structures are basically observed as glycoproteins and glycolipids of cancer cell N-linked and O-linked cell surfaces and reported to be directly related to invasion and metastasis of cancer, and host specific antigen recognition by sialic acid derivatives of anticancer agents It is reported that the sialic acid derivatives of epothilone A are effective in the prevention and treatment of cancer by inhibiting various types of cancer formation and proliferation.

Accordingly, the present invention relates to an anticancer composition containing a sialic acid derivative of epothilone A from a different viewpoint.

The present invention provides a pharmaceutical composition comprising a compound of the present invention and a pharmaceutically acceptable carrier.

Also provided are methods of treating or preventing cancer in a host. The method includes treating or preventing cancer in a host by administering to the host an amount of the compound described above in an amount sufficient to treat or prevent the cancer in the host.

An anticancer composition containing an epothilone A derivative having two or more monosaccharides bonded thereto prepared as described above as an active ingredient may be used. The anticancer composition may be prepared by a conventional method known in the art.

[ Example ]

Hereinafter, the present invention will be described in more detail with reference to Examples. It will be apparent to those skilled in the art that these embodiments are merely illustrative of the present invention and that the scope of the present invention is not limited to these embodiments.

Manufacturing example  1: preparation of enzyme

Uridine diphosphate glucosyltransferase (YjiC) derived from Bacillus licheniformis was recombined into a pET28 expression vector and introduced into E. coli BL21 (DE3) (Stratagene, La Jolla, CA, USA) for the production of enzymes to construct Escherichia coli mutants. Escherichia coli mutants were cultured in LB medium supplemented with kanamycin antibiotics. IPTG was added to 0.8 mM when the cell density (OD600) was 0.6, and the cells were cultured at 20 DEG C for 20 h at 150 rpm to express the enzyme protein Were harvested. The obtained cells were disrupted with an ultrasonic wave crusher and centrifuged at 4 ° C for 30 min at 12,000 rpm to obtain a supernatant. The degree of expression of the enzyme obtained by nickel-affinity chromatography was confirmed by SDS-PAGE gel, and YjiC (Uridine diphosphate glucosyltransferase).

The galactosyltransferase (β1,4-GalT) derived from Helicobacter pylori (ATCC 43504) was recombinantly transfected into the pET24a expression vector and was used by the Seoul National University. Α-2,3-sialyltransferase (α- 3 sialyltransferase, α2,3-SiaT) and α-2,6 sialyltransferase (α2,6-SiaT) were recombined into pET32a and pET15b expression vectors, respectively. For the production of glycosyltransferases, recombinant expression vectors were introduced into Escherichia coli BL21 (DE3) (Stratagene, La Jolla, CA, USA) to construct respective Escherichia coli mutants. Escherichia coli mutants for the production of galactosyltransferase (β1,4-GalT) were cultured in LB medium treated with kanamycin antibiotics. IPTG was added to give 0.5 mM when the cell density (OD 600 ) was 0.6, and the sialic acid transferase Escherichia coli mutants for the production of α2,3-SiaT and α2,6-SiaT were cultivated in LB medium treated with Ampicillin antibiotic and IPTG was added to 0.4 mM at a cell density (OD 600 ) of 0.6 And cultured at 20 ° C for 20 hours to express the respective sugar transferase and harvest the cells. The obtained cells were disrupted with an ultrasonic wave crusher and centrifuged at 4 ° C for 30 min at 12,000 rpm to obtain a supernatant. The degree of expression of the enzyme obtained by nickel-affinity chromatography was confirmed by SDS-PAGE gel, and galactose transfer (? 1,4-GalT),? 2,3-sialyltransferase (? 2,3-SiaT) and? -2,6-sialyltransferase (? 2,6-SiaT) were obtained.

Example  One: Epothilone  A 6-O-? -D-glucoside from galactose binding Epothilone  A derivatives and sialic acid bonds Epothilone  Synthesis of A derivatives

Three kinds of derivatives were synthesized by performing glycosylation on epothilone A 6-O-? -D-glucoside (Epothilone A 6-O-? -D-glucoside, EpoA-Glc) ).

Epothilone A 6-O-? -D-glucoside (EpoA-Glc) was synthesized in the same manner as Epothilone A (Samyang Genex Co.) in the presence of YjiC (Uridine diphosphate glucosyltransferase). ) And UDP-D-glucose (Sigma-Aldrich Chemical Co., St. Louis, Mo., USA).

(Epothilone A 6-O-? -D-glucoside, EpoA-Glc) and UDP-D (Glc) in the presence of galactosyltransferase - Galactosyl epothilone A (lac-epoA) was synthesized by reacting with galactose.

A sialic acid transfer reaction was performed using the fact that galactose was present in the obtained EpoA galactose derivative (lac-epoA).

The sialic acid transfer reaction was carried out continuously after purifying or reacting the obtained EpoA galactose derivative (lac-epoA), and the obtained product was reacted with α-2,3 sialyltransferase, N-acetyl-N-acetyl-N-acetylneuraminic acid (CMP-N-acetylneuraminic acid) in the presence of α-2,6-SiaT or α-2,6 sialyltransferase (3'-sialyllactosyl epothilone A, 3'-SL-epoA) or a sialic acid derivative (6'-sialyllactosyl epothilone A, 6'-SL -epoA).

Example  2: Epothilone  Purification and Analysis of A Derivatives

In Example 1, the reaction mixture of epothilone A and UDP-D-glucose was purified by preparative HPLC, and a reversed phase C 18 column (Mightysil RP-18 GP, 150 x 4.6 mm, kanto chemical, (SPD-M20A Detector) using HPLC-PDA (high-performance liquid chromatography-coupled photo diode array, Shimadzu, Japan) The binary mobile phase consists of solution A, which is an HPLC grade, and solution B, which is 100% methanol. The program was run for 30 minutes while maintaining the flow rate at 1 mL / min. B flow started at 20%, gradually increased to 75% by 15 minutes, increased to 90% between 16 and 22 minutes, then decreased to 50% at 25 minutes, 20% at 28 minutes, Min.

After confirming the product by HPLC-PDA and high resolution LC-QTOF ESI / MS using ACQUITY (UPLC, Water Corp., Billerica, MA, USA) column with SYNAPT G2-S (Water Corp.) 100% MeOH) and solution a (HPLC grade water), 46 minutes with a flow program, two won (binary program) for use by a UV detector (249㎚) connected to C 18 column (YMC-Pack ODS-AQ, 150 x 20mm ID, (Shimadzu, Tokyo, Japan) was further performed. B flow was initially maintained at 20%, increased to 75% by 25 minutes, reduced to 90% between 25 and 35 minutes, then to 50% at 40 minutes and to 20% at 45 minutes and stopped at 46 minutes.

The conversion of purified epothilone A 6-O-? -D-glucoside (Epothilone A 6-O-? -D-glucoside, EpoA-Glc) was about 26%, and HPLC- PDA and cationic high resolution LC- The spectral results The m / z value for [epoA-Glc + H] + was 656.3143 (Figure 2).

Epothilone A 6-O-β-D-glucoside (EpoA-Glc) was synthesized from EpoA galactoside derivatives (Galactosyl epothilone A, lac- epoA) and sialic acid derivatives (3'-sialyllactosyl epothilone A, 3'- '-sialyllactosyl epothilone A, 6'-SL-epoA).

All reaction mixtures were analyzed by HPLC (Dong-il Simazu, Endurosil C 18 column; HPLC) using binary conditions with a total flow of solution A (0.1 M TEAA HPLC grade aqueous solution) and solution B (100% acetonitrile) at 1 mL / min. 205 x 4.6 mm, 5 um). The concentration of solution B started at 20%, decreased to 90% between 25 and 35 minutes, then to 50% at 40 minutes and to 20% at 45 minutes and stopped at 46 minutes. Each reaction mixture was further analyzed by high resolution mass spectrometry (Fig. 3).

EpoA galactose derivative (lac-epoA) and two kinds of sialic acid derivatives (3'-SL-epoA and 6'-SL-epoA) were separated by prep-HPLC SHIMADZU SPD-10Avp (source Q15 resin 200ml, Fine Line Pilot 35 column , The concentration of solution B started at 20%, maintained at 90% between 25 and 35 minutes, 50% at 40 minutes, and 20% at 45 minutes, while keeping the solution at 4 mL / min with Amersham biosciences, Piscataway, NJ, (250 x 10 mm) semi-prep column (Fig. 4), which is an ACE using a binary program of reducing and stopping at 46 minutes.

Analysis of the cationic high-resolution LC-MS spectra revealed that galactose was transferred from UDP-D-galactose to EpoA 6-O-? -D-glucoside in the presence of galactose transporter at an m / z value of 818.3642 (3'-SL-epoA) and 6'-cialyl lactosyl epothilone A (6'-SL-epoA) were synthesized. The m / z values for [3'-SL-epoA + H] + and [6'-SL-epoA + H] + of epoA were 1109.4587 and 1109.4595, respectively, It was confirmed that sialic acid was transferred from neuraminic acid to EpoA galactose (Figs. 5A, 5B and 5C).

After recovery of each analogue from the reaction product, the recovery rate of the product was measured. As a result, about 97.98% of the EpoA galactose derivative (lac-epoA) was recovered and the recovered derivative was a sialic acid derivative of formula (1) 3'-sialyllactosyl epothilone A, 3'-SL-epoA) or a sialic acid derivative of formula 2 (6'-sialyllactosyl epothilone A, 6'-SL-epoA). The purity and yield of the synthesized sialic acid derivative (3'-SL-epoA) or the sialic acid derivative (6'-SL-epoA) of formula (2) were measured by HPLC analysis and found to be about 98.57% %.

Each purified epothilone A derivative was dried and then dissolved in DMSO-d 6 and structurally characterized using 1 H NMR, 13 C NMR nuclear magnetic resonance (900 MHz, Bruker Biospin GmbH, Karlsruhe, Germany) Were compared with NMR results of previously reported vancomycin derivatives (Table 1).

Figure 112015127422312-pat00005

The chemical shifts observed in 1 H NMR were similar to the literature values for epothilone A 6-O- beta -D-glucoside (EpoA-Glc), and the lac-epoA, 3'-SL-epoA, 6'- The signal of each galactose anomeric proton (1-CH) was observed at δ 5.24, 4.61, and 4.64 positions. However, the signals for 9-CH2 of 3'-SL-epoA and 6'-SL-epoA were observed at δ3.28 and 3.11, respectively. 3'-SL-epoA, unusual proton of 6'-SL-epoA neuraminic acid at each have showed little change, as described in TABLE 1, (CH 3 CO -) signal for the δ1.89, 1.87, ( 3-CH 2 ) was observed at δ 1.80 and 1.82 (FIG. 5).

Example  3: MTT  assay

MTT assays were performed to collect the experimental basis of treatment of the epothilone A derivatives obtained in Example 2 above. In detail, MTT assays were performed using HCT116 and HUVEC cell lines to confirm the effect of cytotoxicity reduction on epothilone A aglycone.

As a result, there was no change in the anticancer activity and cytotoxicity of epothilone A according to the concentration, while the epothilone A derivatives of the present invention showed an increase in anticancer activity and a decrease in cytotoxicity depending on the concentration (Fig. 6).

While the present invention has been particularly shown and described with reference to specific embodiments thereof, those skilled in the art will appreciate that such specific embodiments are merely preferred embodiments and that the scope of the present invention is not limited thereby. something to do. Accordingly, the actual scope of the present invention will be defined by the claims and their equivalents.

Claims (3)

A sialic acid derivative of epothilone A represented by the following formula (1) or (2).
[Chemical Formula 1]
Figure 112015127422312-pat00006

(2)
Figure 112015127422312-pat00007

 A method for producing a sialic acid derivative of epothilone A represented by Formula (1) or (2), comprising the steps of:
(a) Epothilone A 6-O-β-D-glucoside (SEQ ID NO: 1) in the presence of β-1,4- , EpoA-Glc) with UDP-D-galactose to prepare an EpoA galactosyl derivative (Galactosyl epothilone A, lac-epoA); And
(b) The above-mentioned EpoA galactose derivative is reacted with an α-2,3 sialyltransferase, α2,3-SiaT or α-2,6 sialyltransferase -acetyl neuraminic acid (CMP-NeuAc) in the presence of a cytotoxic agent such as 3'-sialyllactosyl epothilone A (1, 2, 6-SiaT) , 3'-SL-epoA) or a sialic acid derivative (6'-sialyllactosyl epothilone A, 6'-SL-epoA)
The method according to claim 2, wherein the Epothilone A 6-O-? -D-glucoside (EpoA-Glc) is a glycosyltransferase (Uji) diphosphate glucosyltransferase derived from Bacillus licheniformis . Wherein said epothilone A is produced by reacting epothilone A with UDP-D-glucose.
KR1020150187287A 2015-12-28 2015-12-28 New Sialic Acid Derivatives of Epothilone A and Method for Producing the Same KR101760468B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020150187287A KR101760468B1 (en) 2015-12-28 2015-12-28 New Sialic Acid Derivatives of Epothilone A and Method for Producing the Same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020150187287A KR101760468B1 (en) 2015-12-28 2015-12-28 New Sialic Acid Derivatives of Epothilone A and Method for Producing the Same

Publications (2)

Publication Number Publication Date
KR20170077422A KR20170077422A (en) 2017-07-06
KR101760468B1 true KR101760468B1 (en) 2017-07-21

Family

ID=59354092

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020150187287A KR101760468B1 (en) 2015-12-28 2015-12-28 New Sialic Acid Derivatives of Epothilone A and Method for Producing the Same

Country Status (1)

Country Link
KR (1) KR101760468B1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111205343B (en) * 2020-01-08 2022-06-14 山东大学 Nitrogen acetyl glucoside or galactoside compound of epothilone B, and enzymatic preparation and application thereof
CN111138444B (en) * 2020-01-08 2022-05-03 山东大学 Epothilone B glucoside compounds and enzymatic preparation and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014185717A1 (en) 2013-05-15 2014-11-20 한국생명공학연구원 Novel epothilone derivative and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014185717A1 (en) 2013-05-15 2014-11-20 한국생명공학연구원 Novel epothilone derivative and use thereof

Also Published As

Publication number Publication date
KR20170077422A (en) 2017-07-06

Similar Documents

Publication Publication Date Title
US20220168428A1 (en) Cannabinoid glycoside prodrugs and methods of synthesis
Li et al. Efficient chemoenzymatic synthesis of an N-glycan isomer library
KR20090020697A (en) Water soluble and activable phenolics derivatives with dermocosmetic and therapeutic applications and process for preparing said derivatives
WO2013182206A1 (en) Method for producing oligosaccharides and oligosaccharide glycosides by fermentation
Aljahdali et al. De novo asymmetric synthesis of the pyranoses: From monosaccharides to oligosaccharides
WO2014048439A1 (en) Glycoconjugate synthesis
EP1911850A1 (en) Method of producing 6-thio-sialylated glycoproteins and glycoconjugates
KR101760468B1 (en) New Sialic Acid Derivatives of Epothilone A and Method for Producing the Same
Le et al. Efficient enzymatic systems for synthesis of novel α-mangostin glycosides exhibiting antibacterial activity against Gram-positive bacteria
Parajuli et al. Expanded acceptor substrates flexibility study of flavonol 7-O-rhamnosyltransferase, AtUGT89C1 from Arabidopsis thaliana
Lee et al. Sustainable production of dihydroxybenzene glucosides using immobilized amylosucrase from Deinococcus geothermalis
KR100964944B1 (en) Method for preparing derivatives of glyco-compounds by using glycosyltransferases and the derivatives thereof
Cao et al. General consideration on sialic acid chemistry
Parajuli et al. Enzymatic synthesis of lactosylated and sialylated derivatives of epothilone A
KR101763344B1 (en) Novel Epothilone A derivatives and Uses Thereof
Shimoda et al. Glycosylation of daidzein by the Eucalyptus cell cultures
Darsandhari et al. One-pot multienzyme cofactors recycling (OPME-CR) system for lactose and non-natural saccharide conjugated polyphenol production
US20150133647A1 (en) Method for Producing Oligosaccharides and Oligosaccharide Glycosides by Fermentation
US9045517B2 (en) Glycosylated aminocoumarins and methods of preparing and uses of same
Lu et al. Galactosylation of caffeic acid by an engineered β-galactosidase
KR20220099729A (en) Method for production of quercetin inclusion complex using cyclodextrin glucanotransferase
KR101966882B1 (en) New Glycoside Derivatives of Genistein, Pharmaceutical Compositions for Treating Cancer Diseases Containing The Same and Method for Preparing the Same
KR20150086990A (en) Novel Epothilone Glycosides and Method for Preparing the Same
Wang et al. Synthesis of a mannose-capped disaccharide with a thiol terminus.
KR102390654B1 (en) Preparation method of flavonol-3-isoglycosides

Legal Events

Date Code Title Description
A201 Request for examination
E701 Decision to grant or registration of patent right
GRNT Written decision to grant